Jill Howe - Lineage Cell CFO Officer
| LCTX Stock | USD 0.63 0.03 5.00% |
Insider
Jill Howe is CFO Officer of Lineage Cell Therapeutics
| Age | 49 |
| Phone | 442 287 8990 |
| Web | https://www.lineagecell.com |
Jill Howe Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jill Howe against Lineage Cell stock is an integral part of due diligence when investing in Lineage Cell. Jill Howe insider activity provides valuable insight into whether Lineage Cell is net buyers or sellers over its current business cycle. Note, Lineage Cell insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lineage Cell'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jill Howe over three weeks ago Acquisition by Jill Howe of 10500 shares of Lineage Cell at 0.89 subject to Rule 16b-3 | ||
Jill Howe over three months ago Acquisition by Jill Howe of 10500 shares of Lineage Cell at 0.89 subject to Rule 16b-3 | ||
Jill Howe over six months ago Acquisition by Jill Howe of 650000 shares of Lineage Cell at 1.13 subject to Rule 16b-3 |
Lineage Cell Management Efficiency
The company has return on total asset (ROA) of (0.1286) % which means that it has lost $0.1286 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3504) %, meaning that it created substantial loss on money invested by shareholders. Lineage Cell's management efficiency ratios could be used to measure how well Lineage Cell manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Rhodri Davies | Oxford Nanopore Technologies | N/A | |
| Tanya MS | Replimune Group | 53 | |
| DSc FACP | Ovid Therapeutics | 65 | |
| Karen Kotz | Coherus BioSciences | N/A | |
| Lei Sun | Connect Biopharma Holdings | 61 | |
| Sara Le | Oxford Nanopore Technologies | N/A | |
| SPHR SHRMSCP | Ovid Therapeutics | N/A | |
| Duane BA | Armata Pharmaceuticals | 74 | |
| Thomas Templeman | Nuvation Bio | 60 | |
| Dr Roberts | Lyra Therapeutics | 56 | |
| David Hanley | Nuvation Bio | 55 | |
| Gordon Sanghera | Oxford Nanopore Technologies | N/A | |
| Wenyuan Shi | Armata Pharmaceuticals | N/A | |
| Susannah Walpole | Spero Therapeutics | N/A | |
| Laura Carter | Gossamer Bio | 57 | |
| Michelle Doig | Nuvation Bio | 46 | |
| MBA MD | Spero Therapeutics | 44 | |
| Solomon Langermann | NextCure | 65 | |
| Sergei Gryaznov | MAIA Biotechnology | 65 | |
| MD MBA | MAIA Biotechnology | 55 | |
| Jeffrey Rona | Ovid Therapeutics | 57 | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.13 |
Lineage Cell Therapeutics Leadership Team
Elected by the shareholders, the Lineage Cell's board of directors comprises two types of representatives: Lineage Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lineage. The board's role is to monitor Lineage Cell's management team and ensure that shareholders' interests are well served. Lineage Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lineage Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charlotte Hubbert, Vice Development | ||
| Jill Howe, CFO Officer | ||
| DVM Dvm, VP Affairs | ||
| Alexandra Hernandez, Senior Controller | ||
| William MBA, President Corporation | ||
| JD III, General Secretary | ||
| Ioana Hone, Director Relations | ||
| William Annett, Pres Corp | ||
| Rami Skaliter, Chief Neurosciences | ||
| Harold Waitz, Vice Control | ||
| MBA MA, President CEO |
Lineage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lineage Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (4.17) % | ||||
| Current Valuation | 107.6 M | ||||
| Shares Outstanding | 228.31 M | ||||
| Shares Owned By Insiders | 0.44 % | ||||
| Shares Owned By Institutions | 50.56 % | ||||
| Number Of Shares Shorted | 15.94 M | ||||
| Price To Earning | 3.62 X | ||||
| Price To Book | 2.08 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.